Wansu Chen, Dan Xu, Xueting Shao, Qingxia Song, Renshou Chen
{"title":"西马鲁肽对多囊卵巢综合征患者体重指数(BMI)和血脂水平影响的meta分析。","authors":"Wansu Chen, Dan Xu, Xueting Shao, Qingxia Song, Renshou Chen","doi":"10.1080/09513590.2025.2553052","DOIUrl":null,"url":null,"abstract":"<p><p>Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic disorder in reproductive-aged women, often associated with obesity and dyslipidemia. Semaglutide, a GLP-1 receptor agonist (GLP-1 RA), improves glycemic control and weight, but its effects on PCOS remain unclear. This meta-analysis evaluates semaglutide's impact on BMI and blood lipids in PCOS patients. We searched PubMed, Embase, Cochrane Library, ClinicalTrials.gov, WHO ICTRP, and gray literature sources for RCTs (2010-2025) comparing semaglutide vs. placebo/conventional treatment in PCOS patients. The outcomes included BMI, total cholesterol (TC), triglycerides (TG), LDL-C, and HDL-C. The data were analyzed using RevMan 5.4, with mean differences (MD) and 95% CIs were calculated. Heterogeneity was assessed via I². Eight RCTs (526 patients) were included. Semaglutide significantly reduced BMI (MD: -2.20 kg/m², 95% CI: -2.42 to -1.97, <i>P</i> < 0.001), TC (MD: -0.42 mmol/L, 95% CI: -0.46 to -0.39, <i>P </i>< 0.0001), TG (MD: -0.35 mmol/L, 95% CI: -0.38 to -0.32, <i>P </i>< 0.0001), and LDL-C (MD: -0.31 mmol/L, 95% CI: -0.35 to -0.27, <i>P </i>< 0.0001), but not HDL-C (<i>P</i> = 0.8524). Subgroup analysis showed greater efficacy at doses ≥ 1.0 mg/week and in patients with a baseline BMI > 28 kg/m². Overall evidence quality was moderate to low based on GRADE assessment. Semaglutide significantly improves BMI and lipid profiles in PCOS, particularly at higher doses, and in obese patients. Further long-term studies are needed to confirm safety and reproductive outcomes.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"41 1","pages":"2553052"},"PeriodicalIF":1.7000,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patients.\",\"authors\":\"Wansu Chen, Dan Xu, Xueting Shao, Qingxia Song, Renshou Chen\",\"doi\":\"10.1080/09513590.2025.2553052\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic disorder in reproductive-aged women, often associated with obesity and dyslipidemia. Semaglutide, a GLP-1 receptor agonist (GLP-1 RA), improves glycemic control and weight, but its effects on PCOS remain unclear. This meta-analysis evaluates semaglutide's impact on BMI and blood lipids in PCOS patients. We searched PubMed, Embase, Cochrane Library, ClinicalTrials.gov, WHO ICTRP, and gray literature sources for RCTs (2010-2025) comparing semaglutide vs. placebo/conventional treatment in PCOS patients. The outcomes included BMI, total cholesterol (TC), triglycerides (TG), LDL-C, and HDL-C. The data were analyzed using RevMan 5.4, with mean differences (MD) and 95% CIs were calculated. Heterogeneity was assessed via I². Eight RCTs (526 patients) were included. Semaglutide significantly reduced BMI (MD: -2.20 kg/m², 95% CI: -2.42 to -1.97, <i>P</i> < 0.001), TC (MD: -0.42 mmol/L, 95% CI: -0.46 to -0.39, <i>P </i>< 0.0001), TG (MD: -0.35 mmol/L, 95% CI: -0.38 to -0.32, <i>P </i>< 0.0001), and LDL-C (MD: -0.31 mmol/L, 95% CI: -0.35 to -0.27, <i>P </i>< 0.0001), but not HDL-C (<i>P</i> = 0.8524). Subgroup analysis showed greater efficacy at doses ≥ 1.0 mg/week and in patients with a baseline BMI > 28 kg/m². Overall evidence quality was moderate to low based on GRADE assessment. Semaglutide significantly improves BMI and lipid profiles in PCOS, particularly at higher doses, and in obese patients. Further long-term studies are needed to confirm safety and reproductive outcomes.</p>\",\"PeriodicalId\":12865,\"journal\":{\"name\":\"Gynecological Endocrinology\",\"volume\":\"41 1\",\"pages\":\"2553052\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gynecological Endocrinology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/09513590.2025.2553052\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecological Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09513590.2025.2553052","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
多囊卵巢综合征(PCOS)是育龄妇女中一种常见的内分泌代谢紊乱,常与肥胖和血脂异常有关。Semaglutide是一种GLP-1受体激动剂(GLP-1 RA),可改善血糖控制和体重,但其对PCOS的影响尚不清楚。本荟萃分析评估了西马鲁肽对多囊卵巢综合征患者BMI和血脂的影响。我们检索了PubMed、Embase、Cochrane Library、ClinicalTrials.gov、WHO ICTRP和灰色文献来源的rct(2010-2025),比较了西马鲁肽与安慰剂/常规治疗对PCOS患者的影响。结果包括BMI、总胆固醇(TC)、甘油三酯(TG)、LDL-C和HDL-C。采用RevMan 5.4对数据进行分析,计算平均差异(MD)和95% ci。通过I²评估异质性。纳入8项随机对照试验(526例患者)。Semaglutide显著降低BMI (MD: -2.20 kg/m²,95% CI: -2.42 ~ -1.97, P P P P = 0.8524)。亚组分析显示,剂量≥1.0 mg/周和基线BMI为28 kg/m²的患者疗效更好。根据GRADE评估,总体证据质量为中低。Semaglutide显著改善PCOS患者的BMI和脂质谱,特别是在高剂量和肥胖患者中。需要进一步的长期研究来确认安全性和生殖结果。
Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patients.
Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic disorder in reproductive-aged women, often associated with obesity and dyslipidemia. Semaglutide, a GLP-1 receptor agonist (GLP-1 RA), improves glycemic control and weight, but its effects on PCOS remain unclear. This meta-analysis evaluates semaglutide's impact on BMI and blood lipids in PCOS patients. We searched PubMed, Embase, Cochrane Library, ClinicalTrials.gov, WHO ICTRP, and gray literature sources for RCTs (2010-2025) comparing semaglutide vs. placebo/conventional treatment in PCOS patients. The outcomes included BMI, total cholesterol (TC), triglycerides (TG), LDL-C, and HDL-C. The data were analyzed using RevMan 5.4, with mean differences (MD) and 95% CIs were calculated. Heterogeneity was assessed via I². Eight RCTs (526 patients) were included. Semaglutide significantly reduced BMI (MD: -2.20 kg/m², 95% CI: -2.42 to -1.97, P < 0.001), TC (MD: -0.42 mmol/L, 95% CI: -0.46 to -0.39, P < 0.0001), TG (MD: -0.35 mmol/L, 95% CI: -0.38 to -0.32, P < 0.0001), and LDL-C (MD: -0.31 mmol/L, 95% CI: -0.35 to -0.27, P < 0.0001), but not HDL-C (P = 0.8524). Subgroup analysis showed greater efficacy at doses ≥ 1.0 mg/week and in patients with a baseline BMI > 28 kg/m². Overall evidence quality was moderate to low based on GRADE assessment. Semaglutide significantly improves BMI and lipid profiles in PCOS, particularly at higher doses, and in obese patients. Further long-term studies are needed to confirm safety and reproductive outcomes.
期刊介绍:
Gynecological Endocrinology , the official journal of the International Society of Gynecological Endocrinology, covers all the experimental, clinical and therapeutic aspects of this ever more important discipline. It includes, amongst others, papers relating to the control and function of the different endocrine glands in females, the effects of reproductive events on the endocrine system, and the consequences of endocrine disorders on reproduction